Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Amcad Biomed's 3-Year RORE % for the quarter that ended in Jun. 2026 was -1.72%.
The industry rank for Amcad Biomed's 3-Year RORE % or its related term are showing as below:
ROCO:4188's 3-Year RORE % is ranked better than 52.7% of 778
companies
in the Medical Devices & Instruments industry
Industry Median: -3.755
vs ROCO:4188: -1.72
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Amcad Biomed 3-Year RORE % Related Terms
Amcad Biomed 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4188 vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Amcad Biomed's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Amcad Biomed (ROCO:4188) has a 3-Year RORE % of -1.72 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Amcad Biomed and its competitors. According to the industry distribution chart, Amcad Biomed ranks #368 out of 778 companies in the Medical Devices & Instruments industry, placing it in the top 47.3%.
Is Amcad Biomed's 3-Year RORE % too high?
Amcad Biomed's current 3-Year RORE % is -1.72. Based on the distribution chart, Amcad Biomed ranks #368 out of 778 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Amcad Biomed has a GF Score™ of 48/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #368 out of 778 companies for 3-Year RORE %. This puts Amcad Biomed in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Amcad Biomed and its competitors. Amcad Biomed's current 3-Year RORE % is -1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$9.68, compared to a current price of NT$11.00 — trading 13.6% above its estimated fair value. The current 3-Year RORE % is -1.72. Amcad Biomed's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current 3-Year RORE % is -1.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$11.00 is trading 13.6% above its estimated GF Value™ of NT$9.68.
GuruFocus considers Amcad Biomed to be Modestly Overvalued.
Key valuation signals for ROCO:4188:
3-Year RORE %: -1.72
GF Value™: NT$9.68 vs. price of NT$11.00 (13.6% above fair value)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
48GF Score
Get the complete analysis for ROCO:4188
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
